Guangzhou Baiyunshan Pharmaceutical Holdings Co (SHSE:600332) 3-Year EBITDA Growth Rate : 11.50% (As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Guangzhou Baiyunshan Pharmaceutical Holdings Co 3-Year EBITDA Growth Rate?

Guangzhou Baiyunshan Pharmaceutical Holdings Co's EBITDA per Share for the three months ended in Mar. 2024 was ¥1.57.

During the past 12 months, Guangzhou Baiyunshan Pharmaceutical Holdings Co's average EBITDA Per Share Growth Rate was 1.30% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 11.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 8.50% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 14.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Guangzhou Baiyunshan Pharmaceutical Holdings Co was 33.60% per year. The lowest was -14.90% per year. And the median was 12.20% per year.

Competitive Comparison of Guangzhou Baiyunshan Pharmaceutical Holdings Co's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Guangzhou Baiyunshan Pharmaceutical Holdings Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Guangzhou Baiyunshan Pharmaceutical Holdings Co's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Guangzhou Baiyunshan Pharmaceutical Holdings Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Guangzhou Baiyunshan Pharmaceutical Holdings Co's 3-Year EBITDA Growth Rate falls into.

Guangzhou Baiyunshan Pharmaceutical Holdings Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Guangzhou Baiyunshan Pharmaceutical Holdings Co (SHSE:600332) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Guangzhou Baiyunshan Pharmaceutical Holdings Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Guangzhou Baiyunshan Pharmaceutical Holdings Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Guangzhou Baiyunshan Pharmaceutical Holdings Co (SHSE:600332) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (SHSE:600332) » Definitions » 3-Year EBITDA Growth Rate

Traded in Other Exchanges

00874:Hong Kong

Address

89 Queensway, Room 2005, 20th Floor, Tower Two, Lippo Center, Hong Kong, HKG

Website

https://www.gybys.com.cn

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is active in the Chinese healthcare sector. The company manufactures pharmaceutical products including antibiotics, vasodilators, and traditional Chinese medical therapies in preparations such as injection, tablet, capsule, powder, cream, and oral liquid. Its segment includes Great Southern TCM; Great Health; Great Commerce and others. The company generates maximum revenue from the Great Commerce segment.

Guangzhou Baiyunshan Pharmaceutical Holdings Co (SHSE:600332) Headlines

No Headlines